Patentable/Patents/US-9512207
US-9512207

Anti-NPC2 monoclonal antibodies and a method of detecting fatty liver tissue, cancer cells or cancer tissue by using them

PublishedDecember 6, 2016
Assigneenot available in USPTO data we have
Inventorsnot available in USPTO data we have
Technical Abstract

The present invention is related to anti-NPC2 monoclonal antibodies, which against NPC2 or glycosylated-NPC2; and is related to a method of detecting fatty liver tissues, cancer cells or cancer tissues by evaluating the expression level of NPC2 or glycosylated-NPC2 in the cells or tissues.

Patent Claims

Legal claims defining the scope of protection, as filed with the USPTO.

Claim text for this patent isn't available yet.

Classification Codes (CPC)

Cooperative Patent Classification codes for this invention. Click any code to explore related patents in that topic.

G01N
Patent Metadata

Filing Date

September 22, 2011

Publication Date

December 6, 2016

Want to explore more patents?

Browse 5M+ US patents with plain-English claim translations and AI-generated analysis.

Browse All PatentsTry Prior Art Search
Citation & reuse

Analysis on this page is generated by Patentable — an AI-powered patent intelligence platform. AI-generated summaries, explanations, and analysis may be reused with attribution and a visible link back to the canonical URL below. Patent abstracts and claims are USPTO public domain.

Cite as: Patentable. “Anti-NPC2 monoclonal antibodies and a method of detecting fatty liver tissue, cancer cells or cancer tissue by using them” (US-9512207). https://patentable.app/patents/US-9512207

© 2026 Patentable. All rights reserved.

Patentable is a research and drafting-assistant tool, not a law firm, and does not provide legal advice. Documents we generate are drafts for review by a licensed patent attorney.